A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

NCT07333118 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Refractory Autoimmune Disease

Interventions

BIOLOGICAL: GT801 Injection

Sponsor

Grit Biotechnology

Collaborators

[object Object]